抗原檢測概念股普跌,諾唯贊(688105.SH)收跌逾10%
格隆匯3月16日丨A股三大指數午後在大金融等板塊的帶動下走強,不過,抗原檢測概念股今日全天低迷,截至收盤,諾唯贊(688105.SH)跌逾10%,熱景生物跌逾9%,萬孚生物跌逾8%,華大基因、康泰醫學等紛紛走低。

3月11日,國務院應對新型冠狀病毒肺炎疫情聯防聯控機制綜合組發佈《新冠病毒抗原檢測應用方案(試行)》。申萬宏源發研報指,國內抗原檢測市場打開,“出口+內需”齊發力,上中下游將多方受益,市場空間值得期待。
另據國家藥監局官網,3月15日,經國家藥監局審查,批准2個新冠病毒抗原檢測試劑產品。截至3月16日,國家藥監局已批准12個新冠病毒抗原檢測試劑產品。

諾唯贊14日曾發佈股票交易異常波動公吿,全資子公司諾唯贊醫療生產的新型冠狀病毒抗原檢測試劑盒於近日取得國家藥品監督管理局頒發的《醫療器械註冊證》,並完成醫療器械產品註冊預期用途、增加樣本類型及説明書內容的變更。上述產品的銷售受國家疫情防控與採購政策、檢測需求、新冠疫情變化等多因素影響,同時或將面臨市場激烈競爭的風險,對公司未來業績的持續影響尚無法具體預測。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.